KRAS G12C Colon Cancer: An Allergy History That Picks the Antibody Partner
A childhood spent in tick country left this patient with an allergy that has nothing to do with his cancer and everything to do with which version of his next drug combination is actually safe to give him.
D.K., a 63-year-old man, has hunted and fished the same stretch of wooded land his whole life and has been bitten by ticks more times than he can count, one of which, four years ago, left him with a diagnosis he'd never heard of before: alpha-gal syndrome, an IgE-mediated allergy to galactose- alpha-1,3-galactose, a sugar molecule found in mammalian meat and, notably, incorporated into the Fab portion of cetuximab specifically because of how that antibody is manufactured. He carries an EpiPen for accidental red-meat exposure and had a confirmed, physician-witnessed anaphylactic reaction to a beef-based meal two years ago. His metastatic colon cancer, KRAS G12C-mutant, has progressed through two prior lines of chemotherapy, and molecular testing has now identified him as a candidate for KRAS G12C-targeted therapy — his best remaining systemic option.
CodeBreaK 300 established sotorasib combined with panitumumab as superior to standard salvage chemotherapy for KRAS G12C-mutant metastatic colorectal cancer after prior therapy, with a real progression-free survival benefit; adagrasib combined with cetuximab has shown comparable activity in the same molecular setting through KRYSTAL-1. The two anti-EGFR antibodies are not interchangeable for D.K. specifically: cetuximab, a chimeric mouse-human antibody, carries the alpha-gal oligosaccharide on its Fab fragment and has a well-documented, sometimes severe hypersensitivity association in alpha-gal-sensitized patients — exactly the syndrome he carries a confirmed diagnosis and a witnessed reaction history for. Panitumumab, a fully human antibody, does not carry that same oligosaccharide and does not share this specific risk. The choice of which KRAS G12C inhibitor to pair with which antibody, usually treated as a minor logistical detail, is for him the entire safety question. Neither trial was built to notice the difference, because neither enrolled anyone for whom it mattered — a confirmed alpha-gal-specific IgE and a witnessed anaphylaxis do not make him a difficult candidate for KRAS G12C-targeted therapy, they simply remove one of the two antibody partners it can be given with.
Clinic visit, reviewing molecular results and allergy history
Given his confirmed alpha-gal syndrome, I'd go with sotorasib plus panitumumab. CodeBreaK 300 (Fakih et al., NEJM 2023) validated exactly this combination, panitumumab is fully human and doesn't carry the oligosaccharide cetuximab does, and he gets a real, evidence-supported treatment option without touching his known allergy trigger at all.
I'd raise adagrasib plus cetuximab as an alternative worth naming, since some hypersensitivity reactions to therapeutic antibodies can be managed with premedication and graded administration protocols in carefully selected patients. I want to be clear, though, that I'm raising this to make sure we're not skipping past it rather than actually recommending it — alpha-gal reactions are IgE-mediated and can be severe, and premedication doesn't reliably prevent that mechanism the way it does for some other infusion reactions.
Having said it out loud, I don't think I'd actually choose that path for a patient with his specific reaction history — I'd want the allergist to weigh in directly before anyone considers it further.
His alpha-gal-specific IgE is confirmed positive, and he's had a witnessed, physician-documented anaphylactic reaction — that combination puts him at genuinely elevated risk for a severe reaction on any re-exposure to the same epitope, and cetuximab carries that epitope directly in its structure. I would not recommend cetuximab for him under any premedication protocol. Panitumumab doesn't share this specific risk, and I see no allergy-related reason to avoid it.
Agreed: sotorasib plus panitumumab, with the allergist's direct input documented in the chart as the basis for excluding cetuximab from consideration entirely, rather than as a precaution to revisit later.
The clinical pharmacologist's premedication-protocol suggestion was withdrawn once stated aloud and reviewed against the allergist's assessment — recorded not as a rejected proposal but as a genuine part of the reasoning process, useful precisely because naming it and then setting it aside made the final choice more deliberate than skipping the alternative would have.